Binnopharm Group increased export sales by 17% in the first half of 2025. This is stated in the company's message.
The key growth driver was Uzbekistan, where the company's sales increased by 167%. The markets of Armenia also showed significant growth – by 27% and Belarus – by 24%.
Binnopharm Group has completed the state registration procedure for 46 medicines intended for the Russian and foreign markets. The documents were received in the territories of the CIS countries (Azerbaijan, Moldova, Tajikistan, Turkmenistan, Uzbekistan), as well as in Mongolia. Registration procedures that comply with the requirements of the Eurasian Economic Union (EAEU) and national standards have been completed for the company's key products: antibacterial agents, as well as medicines for the treatment of heart, blood and gastrointestinal diseases.
Binnopharm Group is a Russian pharmaceutical company that develops and manufactures prescription and over—the-counter medicines. Binnopharm Group unites production sites located in various regions of Russia: PJSC Sintez (Kurgan), JSC ALIUM (Obolensk in the Serpukhov district of the Moscow Region), JSC Binnopharm (Zelenograd), JSC Biocom (Stavropol) and a modern R&D center (Krasnogorsk). The company's products can be purchased in 15 countries.
